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Nitric oxide (NO) is an important signaling molecule that plays a key role in maintaining 
vascular homeostasis. Dinitrosyl iron complexes (DNICs) generating NO are widely used 
to treat cardiovascular diseases. However, the involvement of DNICs in the metabolic 
processes of the cell, their protective properties in doxorubicin-induced toxicity remain 
to be clarified. Here, we found that novel class of mononuclear DNICs with functional 
sulfur-containing ligands enhanced the cell viability of human lung fibroblasts and 
rat cardiomyocytes. Moreover, DNICs demonstrated remarkable protection against 
doxorubicin-induced toxicity in fibroblasts and in rat cardiomyocytes (H9c2 cells). Data 
revealed that the DNICs compounds modulate the mitochondria function by decreasing 
the mitochondrial membrane potential (ΔΨm). Results of flow cytometry showed that 
DNICs were not affected the proliferation, growth of fibroblasts. In addition, this study 
showed that DNICs did not affect glutathione levels and the formation of reactive oxygen 
species in cells. Moreover, results indicated that DNICs maintained the ATP equilibrium in 
cells. Taken together, these findings show that DNICs have protective properties in vitro. 
It was further suggested that DNICs may be uncouplers of oxidative phosphorylation in 
mitochondria and protective mechanism is mainly provided by the leakage of excess 
charge through the mitochondrial membrane. It is assumed that the DNICs have 
the therapeutic potential for treating cardiovascular diseases and for decreasing of 
chemotherapy-induced cardiotoxicity in cancer survivors.
Keywords: dinitrosyl iron complexes, donors nitric oxide, heart disease, cell viability, membrane potential
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death worldwide. According to the World 
Health Organization (WHO), CVD are in first place in terms of mortality in the world (WHO 
newsletter, 2015). Cardiovascular death and disability are a significant burden in many economies, 
and despite declining mortality over the past two decades, economic losses due to cardiovascular 
Frontiers in Pharmacology | www.frontiersin.org November 2019 | Volume 10 | Article 1277
ORIgINal REsEaRCH
doi: 10.3389/fphar.2019.01277
published: 11 November 2019
Cytoprotective Effects of DNICs on Cell ViabilityAkentieva et al.
2
disease have risen in low- and middle-income countries (Collins 
et al., 2017). WHO estimates that 17.9 million people die from 
CVD each year, accounting for 31% of all deaths in the world 
(WHO newsletter, 2015; Collins et al., 2017). In particular, 
hypertension is a serious disease that significantly increases the 
likelihood of a heart attack, the risk of stroke, the development 
of renal failure, glaucoma, and blindness. Hypertension is one of 
the leading causes of premature death worldwide (WHO, 2013a). 
In addition, according to WHO statistics, 7.4 million people died 
from coronary heart disease and 6.7 million people from stroke 
(WHO, 2013a; WHO, 2013b). The pathology of the cardiovascular 
system is an extremely urgent problem, since it determines more 
than half of the cases of disability and adult mortality (WHO, 
2013a; WHO, 2013b; WHO newsletter, 2015; Collins et al., 
2017). In addition, cardiotoxicity due to chemotherapy is one of 
the most significant side effects in the treatment of cancer and 
causes significant mortality among cancer survivors. Oncological 
diseases are in second place after CVD by mortality (Zaorsky 
et al., 2017). Cancer causes a significant proportion of deaths 
worldwide and in particular in the United States of America 
and Russia (Siegel et al., 2014; Zaorsky et al., 2017). According 
to statistics more than 8 million people died from cancer in 
2013. Cancer mortality has moved from the third leading cause 
of death in 1990 to the second leading cause of death in 2013, 
following heart disease (Coleman et al., 2003). It should be 
noted that modern antitumor therapy, including chemotherapy, 
radiation therapy, and targeted therapy, save life and allow 
social adaptation of cancer patients for decades. However, in the 
treatment of cancer there is an effect on the heart tissue that leads 
to a very serious complication—toxic cardiomyopathy (Łacko 
et al., 2002). Among the side effects of chemotherapeutic agents 
on the cardiovascular system, the most common and serious is 
heart failure with systolic ventricular dysfunction. In addition 
other toxic effects include myocardial ischemia, systolic or 
diastolic myocardial dysfunction, cardiomyopathy, chronic heart 
failure, arterial or pulmonary hypertension, strokes, pericarditis, 
arrhythmias, thromboembolic disease, and others, extremely 
adversely affecting the prognosis of these patients (Łacko 
et al., 2002; Adão et al., 2013; Truong et al., 2014). For several 
decades, cardiomyopathy caused by chemotherapy for cancer 
was mainly due to the use of cumulative doses of anthracyclines 
(doxorubicin, epirubicinum), and trastuzumab, which are the 
chemotherapeutic agents with the most pronounced cardiac side 
effects (Łacko et al., 2002; Adão et al., 2013; Truong et al., 2014; 
Zaorsky et al., 2017; Carrillo-Larco and Bernabe-Ortiz, 2018; Fidale 
et al., 2018; Ng et al., 2018).
Studies in the field of molecular cardiology have established the 
central role of nitric oxide (NO) in the regulation of vascular tone 
of the cardiovascular system and myocardial metabolism (Murad, 
1999; Jose et al., 2013). NO is a gaseous lipophilic molecule generated 
in cells by three different isoforms of nitric oxide synthases (NOS): 
neuronal (nNOS), inducible (iNOS) and endothelial NOS (eNOS) 
(Shibata et al., 2013). The NO molecule is a signal bioregulator that 
affects various physiological and pathological processes in the cell 
(Chatterjee et al., 2008; Shibata et al., 2013).
NO plays an important role in protecting the body from 
the onset and development of cardiovascular diseases. The NO 
molecule is involved in the regulation of the tone of small and 
medium blood vessels, vasodilation, promotes relaxation of 
smooth muscles, exhibits anticoagulant properties, suppresses 
adhesion of monocytes and platelets and production of 
vasoconstrictors, inhibits oxidation of low-density lipoproteins 
and synthesis of cytokines, and affects immune response and 
neurotransmission (Naseem, 2005; Park et al., 2019; Raffetto 
et al., 2019; Tegeder, 2019). The concentration of NO is the 
key factor that determines its biological effect (Wink and 
Mitchell, 1998; Davis et al., 2001; Komatsu et al., 2018). At high 
concentration (>1 μmol) NO is known to have a cytotoxic effect 
due to formation of the highly reactive compound peroxynitrite 
(Ferrer-Sueta et al., 2018). At low concentrations (<1 µmol), 
NO exhibits cytoprotective properties and maintains the 
homeostasis of the cardiovascular and nervous systems (Davis 
et al., 2001; Naseem, 2005; Komatsu et al., 2018; Raffetto et al., 
2019; Tegeder, 2019). The cardioprotective functions of NO are 
aimed at regulating blood pressure, vascular tone, inhibit platelet 
aggregation and leukocyte adhesion, and prevent proliferation of 
smooth muscle cells (Xia and Vanhoutte, 2011; Omar et al., 2016; 
Hou et al., 2019; Taysi et al., 2019). Decreased production and 
bioavailability of NO is a hallmark of many underlying chronic 
diseases, including hypertension, ischemia–reperfusion injury, 
atherosclerosis, and diabetes (Ferrer-Sueta et al., 2018). Violation 
of the bioavailability of NO leads to a loss of cardioprotective 
effect and, in some cases, can even enhance the progression of 
the disease. This deficiency of NO is mainly caused by impaired 
functioning of NO synthetases and increased NO uptake due to 
the formation of reactive oxygen species (ROS).
Currently, in cardiology for the treatment of coronary heart 
disease, drugs that are donors of NO are widely used (Keefer, 
2011; Hou et al., 2019; Xia and Vanhoutte, 2011). NO is a 
cardioprotective mediator in various cardiological processes, 
such as ischemia, hypertension, stroke, and others (Xia and 
Vanhoutte, 2011). Recently, a novel mitochondria-targeted 
superoxide-responsive donor NO was developed, providing 
significant protection against ischemic/reperfusion damage in 
rat cardiomyocytes (H9c2 cells) and isolated rat hearts (Hou 
et al., 2019).
The most common drugs in term of treatment cardiovascular 
disease are nitroglycerin, nitrosorbid, nitroprusside, and nitrite, 
which release NO in cells and tissues during their metabolism 
(Münzel and Schulz, 2010; Kapelko et al., 2017; Gatzke et  al., 
2018; Liu et al., 2019; Lu et al., 2019; Zhao et al., 2019). However, 
these drugs are often unstable, non-specific, toxic, and have a 
number of side effects (Tardiolo et al., 2019). Common known 
side effects of nitrate therapy include headache, flushing, 
lightheadedness, and postural hypotension (Divakaran and 
Loscalzo, 2017). In addition these drugs have many others 
disadvantages, for example, sodium nitroprusside demonstrated 
cyanide toxicity, altered mental status, seizure, metabolic acidosis, 
and nitrosorbide, nitroglycerin can induce methemoglobinemia, 
fatigue, and lethargy (Paul et al., 1986; Shumaev et al., 2018). 
In recent years, the interest in the study of nitrosyl complexes 
of transition metals, particularly iron complexes possessing 
cytoprotective properties, increases exponentially (Lewandowska 
et al., 2011). However, such compounds are often poorly soluble 
Frontiers in Pharmacology | www.frontiersin.org November 2019 | Volume 10 | Article 1277
Cytoprotective Effects of DNICs on Cell ViabilityAkentieva et al.
3
in water, short-lived and toxic to the body (Kapelko et al, 2017). 
Additionally, molecular mechanism of their action and the 
metabolic effects in cells are not well understood. Therefore, the 
development of new cardiac drugs with new improved properties 
is very important for the treatment of cardiovascular diseases. 
Additionally, cardiac failure often develops during the treatment 
of cancer patients because of the high toxicity of anticancer drugs 
(Reis-Mendes et al., 2015; Kuriakose et al., 2016; Hrynchak et al., 
2017; Cuomo et al., 2019; Wenningmann et al., 2019). Heart 
failure is one of the most harmful clinical manifestations of 
cardiotoxicity, and heart failure can occur immediately or appear 
years after chemotherapy treatment.
Therefore, the development of new cardiac drugs with 
cardioprotective properties without side effects that can be used 
to treat cancer with the aim of maintaining the function of the 
cells of the cardiovascular system and the whole organism is 
of particular importance. These drugs can be used in cardiac 
oncology to reduce the cardiac toxic effects of chemotherapy 
drugs. A development of new strategies for reduction of cardiac 
toxicity has great clinical impact.
Thus, the synthesis of drugs that reduce the toxic effects 
of chemotherapy and enhance the viability of normal cells 
(fibroblasts and cardiomyocytes) is a relevant problem in 
cardiology and oncology.
The purpose of this study was to synthesize water soluble 
cationic dinitrosyl iron complexes (DNICs), to study their 
cytoprotective properties in vitro (in particular, the effect 
on the viability and metabolic processes in human lung 
fibroblasts and rat cardiomyocytes, and assess the efficiency 
of the therapeutic action of DNICs. The objectives of this 
study were to establish the effect of DNICs on mitochondrial 
membrane potential, ATP synthesis, glutathione level, ROS, 
viability and proliferation of human lung fibroblasts and 
rat cardiomyocytes.
MaTERIals aND METHODs
Reagents
In this work, the following reagents were used: Dulbecco’s 
Modified Eagle Medium (DMEM, low glucose-1 g/l for culturing 
fibroblasts), L-glutamine, 25 mM HEPES, sodium pyruvate, 
fetal bovine serum (FBS, ultra-low endotoxin content), Trypsin 
0.25%, EDTA 0.02% in HBSS, Gentamicin (10 mg/ml) were 
purchased from Biowest (France). DMEM (high glucose-4.5 g/l 
for culturing rat cardiomyocytes) was purchased from OOO NPP 
PanEko (Russia). AlamarBlue® Cell Viability Reagent; 5,5′,6,6′- 
tetrachloro-1,1′,3,3′- tetraethylbenzinidazolylcarbocyanine iodide 
(JC-1 dye); 2′, 7′- dihydrodichlorofluorescein diacetate 
dye (H2-DCFDA); propidium iodide (PI) were purchased from 
Molecular Probes Company (Eugene, USA). O-phthalaldehyde was 
purchased from Fisher Scientific Company (Loughborough, UK).
Cell lines
The human lung embryonic fibroblasts (HLEF, cell line HLEF-
104) were purchased from BioloT (St. Petersburg, Russia). 
Rat cardiomyocytes (cell line H9c2) were purchased from ATCC 
(Manassas, Virginia, Merck, USA).
Cell Culture
Cells were cultured in DMEM supplemented with 10% fetal 
bovine serum (FBS, vol/vol), glutamine (0.15%), HEPES (10 mM, 
pH 7.2) and gentamicin (50 mg/ml).
Cells were grown in plastic tissue culture flasks (Corning 
Incorporated, Corning, NY, USA) in an atmosphere of 5% CO2 
at 37 °C and 90% humidity. Cells were reseeded twice a week. 
For all experiments, cells from exponentially growing cultures 
were used. After the cells in the monolayer reached a density 
of 90%, they were treated with 0.25% trypsin and EDTA and 
centrifuged at 3,000 g for 5 min. The supernatant was discarded, 
and the cell pellet was re-suspended in growth medium and 
the cells were plated in a 96-well plate. All experiments were 
performed using an HLEF-104 culture <20 passages and an 
H9c2 culture <25 passages.
Preparation of Cell lysates
Human lung embryonic fibroblasts (cell line HLEF-104) were 
cultured in DMEM medium with 10% FBS at 37 ºC and 5% 
CO2. Cells were grown to a density of 90% in culture flasks. 
When confluence of 90% was achieved, cells were treated with 
0.25% trypsin-EDTA, precipitated by centrifugation at 3,000 g 
for 5 min. Then, the resulting cell pellet was re-suspended in 
phosphate buffer (PBS, 0.1 M, pH 7.4), and cell lysates were 
prepared. The cell lysates were prepared by five times pushing 
the cells PBS (0.1 M, pH 7.4.) through a needle of a syringe 
(needle diameter was 25 G). The protein concentration (1.5 
mg/ml) was determined with the Biuret test. The cell lysates 
were used to determine the activity of ATPase and total 
amount of ATP.
synthesis of the DNICs
Water-soluble cationic mononuclear DNICs (#3-[Fe(SC(N
H2)2)2(NO)2]2Fe2(S2O3)2NO4; #4 -[Fe(SC(NH2)(NHC2 
H5))2 (NO2)]Cl[Fe(SC(NH2)(NHC2H5 ))Cl(NO2)]; #6-[Fe 
(SC(NH2)2)2(NO)2]ClO4Cl) with functional sulfur-containing 
ligands, thiourea were synthesized as described in protocol 
(Sanina et al., 2015; Sanina et al., 2019). The structure of 
DNICs was studied by X-ray analysis, Mössbauer, IR and EPR 
spectroscopy (Emel’yanova et al., 2015; Sanina et al., 2015; 
Shmatko et al., 2017b). When dissolved in water solvents, 
these DNICs release NO as a result of dissociation (Sanina 
et al., 2015).
Electrochemical Determination of NO, 
generated From DNICs
The amount of NO generated by DNICs (#3, #4 and #6) in 
solution was carried out using sensor electrode “amiNO-700” of 
the system “in NO Nitric Oxide Measuring System” (Innovative 
Insruments, Inc., Tampa, FL, USA) in accordance with the 
previously described method (Sanina et al., 2015).
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Cell Viability assay
The effect of DNICs on the cell viability was analyzed using 
the AlamarBlue® Cell Viability Assay (ThermoFisher Scientific, 
United States). This method makes it possible to determine 
the activity of mitochondrial NADH dehydrogenases, which 
cleave NADH to NAD and H+, and the formed proton reduces 
the dye resazurin to fluorescent rezofurin (Schreer et al., 2005). 
Fibroblasts (4,000 cells per well) or rat cardiomyocytes (4,500 cells 
per well) were seeded on a 96-well plate and grown overnight in 
an incubator atmosphere of 5% CO2 at 37 °C and 90% humidity. 
The next day, the growth medium was replaced with a new one in 
the wells and DNICs (2 × 10-4 M) were added to cells. DNICs (2 × 
10-4 M) were dissolved in water immediately prior to adding, and 
an equal volume of PBS (0.1 M, pH 7.4) was added to the control 
wells. Then plate with samples was incubated at 37 °C for 20 min. 
Thereafter, doxorubicin (1.4 × 10-4 M) was added to the cells. 
The plate with samples were again incubated at 37 °C for 20 min. 
AlamarBlue® reagent (10 µl) was then added to the cells in each 
well, and fluorescence intensity was measured for 35 h at Eex/
Eem = 570/590 nm using a Varian Cary Eclipse spectrofluorimeter 
(Agilent Technologies, United States). Data are presented as the 
average of three repeated experiments.
Determination of Mitochondrial 
Membrane Potential
DNIC-induced mitochondrial membrane potential 
changes (∆Ψm) were determined using a fluorescent 
lipophilic cationic probe 5, 5′,6, 6′-tetrachloro-1,1′,3,3′- 
tetraethylbenzinidazolylcarbocyanine iodide, JC-1dye. 
This method is based on the fact that JC-1 accumulates in 
mitochondria in proportion to ΔΨm, forming aggregates that 
exhibit red fluorescence. However, in the cytoplasm, JC-1 
exists as monomers, and exhibits green fluorescence. It has 
been established that the ratio of red to green fluorescence is 
proportional to ΔΨm (Lisa et al., 1995; Ganguly et al., 2010). 
Fibroblasts (4,000 cells per well) or rat cardiomyocytes (4,500 cells 
per well) were supplemented with a solution of DNICs (2.0 × 10-4 
M), the control wells were supplemented with an equal volume of 
PBS (0.1 M, pH 7.4.), and the plates were incubated for 15 min. 
Then, JC-1 (2.6 × 10-5 M) was added in the dark, and the plates 
were incubated at 37 °C for 30 min. Intensity of red fluorescence 
(excitation, 570 nm; emission, 595 nm) and green fluorescence 
(excitation, 485 nm; emission, 535 nm) was measured using a 
Varian Cary Eclipse spectrofluorimeter (Agilent Technologies, 
USA) (Ganguly et al., 2010). Data are presented as the average of 
three repeated experiments.
Intra Cellular ROs accumulation study
The level of ROS formation in cells by the action of 
DNICs was assessed by fluorometric method, using 2,7′- 
dihydrodichlorofluorescin diacetate (H2-DCFDA, Molecular 
Probes, USA) (Oksvold et al., 2002). H2-DCFDA is a 
nonfluorescent, cell-permeant compound. When H2-DCFDA 
enters the cell, endogenous esterases within the cell cleave the 
acetate groups, thereby capturing the reduced form of the probe 
(DCHF) intracellularly. It is known that the probe can be readily 
oxidized to DCF by H2O2 or OH- to form a fluorescent compound. 
Briefly, DNICs (2.0 × 10-4 M) were added to fibroblasts (4,000 
cells per well) and rat cardiomyocytes (4,500 cells per well), and 
equal volumes of PBS (0.1 M, pH 7.4) were added to the control, 
then the plate was incubated for 15 min at 37 °C. The cells were 
then washed twice with PBS (0.1 M, pH 7.4), then H2-DCFDA 
(10 μmol, 10 μl) was added to the wells and incubated for 30 min 
at 37 °C in the dark. Then the cells were washed twice in PBS 
(0.1 M, pH 7.4) at 24 °C for 5 min. After that, the fluorescence 
intensity was measured at wavelengths of excitation and emission 
of the oxidized form, at 488 nm and 525 nm, respectively.
Data are presented as the average of three repeated 
experiments.
Determination of Intracellular gsH 
Contents
The influence of DNICs on the level of cellular GSH was carried 
out by modification of a previously published method (Hissin 
and Hilf, 1976; Banerjee et al., 2017). The effect of DNICs on 
the level of intracellular reduced glutathione was assessed 
using o-phthalaldehyde. The principle of the method is that the 
amino groups and sulfhydryl groups of glutathione react with 
o-phthalaldehyde and reduce it to form a fluorescent product. 
Briefly, fibroblasts (4,000 cells per well) and rat cardiomyocytes 
(4,500 cells per well) were seeded into a 96-well plate and cells 
were grown for 24 h in an incubator at 37 °C, 5% CO2. Then, 
cells were treated with DNICs (2 × 10-4 M), the control samples 
were supplemented with an equal volume of PBS (0.1 M, pH 
7.4.) and the plates were incubated for 15 min at an incubator 
at 37 °C, 5% CO2. Then the cells were washed twice with PBS 
(0.1 M, pH 7.4) and a solution of cold distilled water (400 μl) 
containing 17.5% HPO3 was added to them. After incubation for 
10 min the solution was removed and o-phthalaldehyde (100 μl, 
0.1% in ethanol) was added to the cells, incubated for 15 min at 
37 °C. After that, the fluorescence adduct GSH was determined 
at wavelengths (excitation, 350 nm; emission, 420 nm) using a 
Varian Cary Eclipse spectrofluorimeter (Agilent Technologies, 
USA) (Ganguly et al., 2010). Data are presented as the average of 
three repeated experiments.
Cytotoxicity of DNICs
Cytotoxicity of DNICs was determined by staining the cells 
with the aniline dye trypan blue (Venkataraman, 1956). Human 
lung embryonic fibroblasts (cell line HLEF-104) were grown in 
culture flasks in DMEM growth medium in an incubator at 37 °C 
in a 5% CO2 atmosphere. The number of living and dead cells 
was counted by staining the cells with trypan blue. To assess the 
cytotoxicity of DNICs, cells (25,600 cells/ml) were supplemented 
with DNICs (2 × 10-4 M) and incubated for 24 h. HLEF cells 
(25,600 cells/ml) without DNICs served as a control. Then cells 
were treated with 0.25% trypsin-EDTA, aliquots (0.2 ml of the 
cell suspension) were mixed with a trypan blue solution (0.1 ml 
of 0.5% solution in 0.9% NaCl) and incubated with the dye for 
10 min at 37 °C. The number of living and dead cells and the total 
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number of cells was determined in a standard hemocytometer 
chamber. The cytotoxic index (CTI) was calculated by the 
formula: (number of dead cells/total number of cells) × 100%. 
Data are presented as the average of three repeated experiments.
Cell Cycle analysis
The effect of DNICs on the cell cycle was studied by flow cytometry 
(Ormerod et al., 1998). Briefly, fibroblasts were grown in culture 
flasks to a density of 106 cells. Then DNICs (2 × 10-4 M) were 
added to the experimental vial, and an equal amount of growth 
medium was added to the control vial (positive control) and 
incubated for 24 h at 37 °C in 5% CO2. After this, the cells were 
pelleted by centrifugation at 3,000 g for 5 min, the supernatant 
was discarded, and the cell pellet was washed with PBS (0.1 M, 
pH 7.4). Then the cells were fixed cooled to -20 °C with 70% 
ethanol (2 ml) and incubated for 4 h at -20 °C. After incubation, 
the cells were washed twice in PBS (0.1 M, pH 7.4.), incubated for 
30 min at 24 °C with RNase A (0.1 mg/ml) and propidium iodide 
(0.01 mg/ml), Triton X-100 (0.1%). A portion of the cells was left 
as negative control (unstained cells). The cell cycle distribution 
was determined using a FACS (Calibur Flow Cytometer, Becton 
Dickinson, USA). After staining, samples were analyzed using 
flow cytometry on a Guava EasyCyte System (Millipore) Guava® 
Cell Cycle. The fluorescence intensity of propidium iodide was 
measured at Ex/Em = 488/585 nm. The analysis was performed 
using Guava Soft ™ 3.1.1 (Millipore, USA). The fluorescence 
intensity of propidium iodide was presented on the histogram 
in the G0/G1, S and G2/M phases of the cell cycle. Ten thousand 
events were analyzed for each sample. Appropriate gating was 
used to select the single-cell population. The same gate was used 
on all samples, ensuring that the measurements were taken on 
a standard cell population. Data are presented as the average of 
three repeated experiments.
Measurement of aTPase activity
ATPase activity was measured in cell lysates by the colorimetric 
method using the ATPase activity analysis kit (BioVision Kit, 
USA) in accordance with the attached manual. Briefly, whole cells 
(2 × 106) were quickly homogenized with a buffer (400 μl) cooled 
on ice and the samples were placed on ice for 10 min. Then the 
samples were centrifuged at 10,000 g at 4 °C for 10 min and the 
supernatant was collected. Endogenous phosphate removed by 
using ammonium sulfate method. Then samples (20 μl, protein 
1.5 mg/ml) added in triplicates onto a clear 96-well plate (labeled 
“background control”, and “sample ATPase activity”). DNICs 
(2 × 10-4 M) were added to tested samples and incubated 15 min 
on ice. For reagent control ATPase assay buffer (100 µl) added. 
ATPase Positive Control (10 µl) diluted into of ATPase assay 
buffer (190 µl). Then of ATPase Positive Control (20 μl) added 
into wells and adjusted final volume to 100 µl with ATPase assay 
buffer. For each well, 100 μl of a reaction mixture containing 
ATPase assay buffer (98 μl) and ATPase substrate (2 μl) was 
prepared. Then 100 μl of the reaction mixture was added to each 
well, for a positive control, reagent control and test samples, and 
incubated at 25 °C for 30 min. Measurement: added 30 µl ATPase 
assay developer to all standards, ATPase positive control and test 
samples and sample background controls, incubated at 25 °C for 
30 min and measured absorbance (OD) at 650 nm at the end 
of incubation time. Calculation: plotted the phosphate standard 
curve. The sample background is corrected by subtracting a 
higher value obtained from background control or reagent 
control from all sample readings. The ATPase activity of the 
tested samples was calculated: ΔOD = A2 - A1. We used ΔOD 
to the standard phosphate curve to obtain B nmol of phosphate 
generated by ATPase during the reaction time (e.g. t = 30 min). 
The formula was used to calculate the activity of an ATPase 
sample = B/(tX V) × D = nmol/min/μl = mU/μl = U/ml. Where: 
B is the amount of phosphate from the standard curve (nmol), t 
is the reaction time (min), V is the volume of the sample added to 
the reaction well (μl), D is the dilution factor of the sample. Unit 
definition: one ATPase unit is the amount of enzyme that will 
generate 1.0 µmol phosphate per min at pH 7.5 at 25 °C. Data are 
presented as the average of three repeated experiments.
Measurement of Total aTP
The total amount of ATP was measured in cell lysates by 
a fluorometric method using the ab83355 ATP assay kit 
(Abcam, USA) in accordance with the manual. The analysis 
is based on phosphorylation of glycerol in order to obtain a 
product that can be easily quantified fluorometrically (Ex/
Em = 535/587 nm) (Gregorczyk et al., 2018). Briefly, fibroblasts 
were seeded and grown in culture flasks to a density of 106 
cells and treated with DNICs or untreated (positive control). 
DNICs (2 x 10–4 M) was added to the experimental flask, and 
an equal amount of growth medium was added to the control 
flask and incubated for 15 min at 37 °C and in 5% CO2. 
Then prepared cell lysates according to protocol. The growth 
medium was removed and the cells (1 × 106) were washed with 
cold PBS (0.1 M, pH = 7.2) and re-suspended in 100 μl of ATP 
assay buffer. Then the cells were destroyed by pipetting up and 
down a few times. After this, the cells were centrifuged for 5 
min at 4 °C at 13,000 g in a cold micro-centrifuge to remove 
any insoluble material. Supernatants collected and transferred 
to new tubes, kept on ice. Cells samples may contain enzymes 
that can interfere with the assay. To remove these enzymes 
from samples Deproteinizing Sample Preparation Kit – TCA 
(ab204708, USA) has been used. Then the samples (50 μl, 
protein 1.5 mg/ml) were added to a 96-well plate (labeled 
“background control” and “ATP samples”), and adjusted final 
volume to 100 µl with ATP assay buffer. For each well, 50 μl of 
the reaction mixture containing ATP assay buffer (45.8 μl) + 
ATP probe (0.2 μl), ATP converter (2 μl), developer mix 
(2 μl) was prepared and added to each well. The background 
reaction mixture was the same, but without the ATP converter 
(in the absence of an ATP converter, the analysis detects only 
glycerol phosphate, but not ATP).Then we added 50 µL of 
background reaction mix into the background control sample 
wells. Samples were mixed and incubated at room temperature 
for 30 min in the dark. Then immediately measured output 
on a microplate reader at Ex/Em = 535/587 nm. Calculations: 
subtracted the sample background control from sample 
readings. The adjusted values  for each standard are plotted 
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against the final ATP concentration. Standard curve was used 
for adjusted relative fluorescence of the sample to obtain the 
amount of ATP (B) in the sample wells. Concentration of 
ATP (nmol/µl or µmol/ml or mM) in the test samples was 
calculated as: ATP concentration = (V/B × D) × DDF. Where: 
B = amount of ATP in the sample well calculated from standard 
curve (nmol or mM); V = sample volume added in the sample 
wells (µl); D = sample dilution factor if sample is diluted to fit 
within the standard curve range (prior to reaction well set up); 
DDF = deproteinization dilution factor. Data are presented as 
the average of three repeated experiments.
statistical analysis
The analyses were repeated at least three times. Mean ± standard 
deviation (SD) was adopted to present the results. For comparison 
between control and treatment groups, data were calculated 
using one-way analysis of variance (ANOVA) followed by the 
Tukey’s test. A value of P ≤ 0.05 was considered significant. All 
experiments were repeated three times.
REsUlTs
synthesis of DNICs
New family of cationic water soluble DNICs with S-donor 
ligands, such as thiocarbamide and its derivatives was obtained 
and characterized (Sanina et al.,2014, Sanina et  al., 2015; 
Sanina et al., 2016; Shmatko et al., 2017a). These complexes 
are models of the active sites of nitrosyl non-heme [Fe–S] 
proteins existing in all living organisms, from bacteria to 
mammals (Butler and Megson, 2002; Lewandowska et al., 
2011). Their structure and properties have been studied 
by X-ray analysis, IR-, Mössbauer-, and EPR-spectroscopy 
(Figure 1, Supplementary Material) (Shmatko et al., 2017b). 
It was shown that these DNICs are effective NO donors and 
have more than twice high NO-generating ability compared to 
the commercial NO-donor diethylenetriamine (Figures 2–4, 
Supplementary Material) (Sanina et al., 2014; Sanina et al., 
2015). In this study, DNICs were synthesized according to the 
previously described protocol (Sanina et al., 2015). Then, NO 
release from DNICs complexes was investigated. Weighted 
portions (2×10-4 M) DNICs were prepared and dissolved in 
water. After that, the formation of NO was measured using the 
electrochemical method. First, the release of nitric oxide was 
analyzed using the DNIC # 3 complex (Figure 1). As can be 
seen from Figure 1, when DNIC # 3 was dissolved in water, 8 
nmol of NO was released for 50 s, then after 100 s the level of 
NO dropped to 7 nmol and remained constant for 500 s. The 
release of NO from DNIC#6 in an aqueous solution was also 
investigated (Figure 1). It was shown that when DNIC#6 was 
dissolved in an aqueous solution, 16 nmol NO was released 
for 50 s, then after 100 s the NO level dropped to 12 nmol and 
remained constant for 500 s. These results showed that when 
dissolving DNICs in water, the actual concentration of released 
NO is 7–12 nmol for 500 s.
Effect of DNICs on Cell Viability of 
Fibroblasts and Rat Cardiomyocytes
Studies have shown that various types of NO donors 
spontaneously generate NO under physiological conditions 
and exhibit protective effects against ischemia or reperfusion 
injury in cardiomyocytes (H9c2 cell line) and isolated rat hearts 
(Hou et al., 2019; Webb et al., 2004). We studied the short-term 
and long-term effects of DNICs on cell viability. In this study, 
two cell lines (fibroblasts and rat cardiomyocytes) were used to 
determine whether DNICs possess cytotropic properties. The 
effect of DNICs (#3, #4, and #6) on cell viability was evaluated 
using the AlamarBlue® Cell Viability fluorescence assay. As can 
be seen from Figure 2A, DNICs (#3, #4 and #6) increased the 
viability of fibroblasts, since after 15 min there was an increase 
in fluorescence intensity. The viability of rat cardiomyocytes 
also increased 15 min after treatment with DNICs, compared to 
control cells not treated with these compounds (Figure 2B).
We also investigated the effect of DNICs on cell viability 
over time (up to 35 h). The results showed that the viability 
of fibroblasts under the action of DNICs (#3, #4, and #6) 
gradually increased and reached its maximum value after 10 h 
(P < 0.05, Figure 3A). Compound # 3 increased the viability 
of fibroblasts significantly (~ 8 times), and compounds #4 and 
#6 increased it 4.5 times, compared to the control cells that 
were not treated with DNICs. Then after 10 h viability slowly 
decreased, however, remained higher than in cells untreated 
with DNICs (Figure 3A). It was found that DNICs (#3, #4, and 
#6) also increased the viability of rat cardiomyocytes (P < 0.05, 
Figure 3B). As can be seen from Figure 3B the viability of rat 
cardiomyocytes after treatment with DNICs increased by 2 
fold, compared with control cells without treatment with these 
compounds. After 10 h, the viability of rat cardiomyocytes 
treated with DNICs reached a maximum value (12 relative 
units). Thus, long incubation of rat cardiomyocytes with 
FIgURE 1 | The time dependence of NO amount generated by DNIC#3 
and DNIC#6 in aqueous solutions at pH 7 and T = 25 °C under anaerobic 
conditions. The DNICs concentration was (2 × 10-4 M). The values presented 
are the means ± SD of three independent experiments, n = 3.
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DNICs led to a significant increase in their viability and even 
after 35 h it remained at a high level compared to control cells 
(Figure 3B). The exact values  of the fluorescence intensity 
after short-term and long-term treatment of DNICs cells are 
presented in Table 1. These results demonstrated that DNICs 
increased significantly the cell viability of fibroblasts and 
rat cardiomyocytes, suggesting the DNICs have cytotropic 
properties. Since the AlamarBlue® Cell Viability Assay was 
based on the determination of the activity of mitochondrial 
dehydrogenases, we have shown that DNICs increased the 
activity of mitochondrial NADH dehydrogenases, which 
play a central role in cellular energy production (Efremov 
et al., 2010). Therefore, these results indicate that DNICs are 
cytotropic agents.
FIgURE 2 | Effect of DNICs on the cell viability of human lung embryonic fibroblasts (cell line HLEF-104) (a) and rat cardiomyocytes (cell line H9c2) (B) for 60 min. 
DNICs (2 × 10-4 M) were added to cells, then cell viability was tested in fibroblasts and rat cardiomyocytes by AlamarBlue® Cell Viability Assay. *P ≤ 0.05 vs. control 
group, with ANOVAs followed by Tukey’s post hoc test. The values presented are the means ± SD of four independent experiments, n = 4.
FIgURE 3 | Effect of DNICs on the cell viability of human lung embryonic fibroblasts (cell line HLEF-104) (a) and rat cardiomyocytes (cell line H9c2) (B) for 35 h. 
DNICs (2 × 10-4 M) were added to cells, then cell viability was tested in fibroblasts and rat cardiomyocytes by AlamarBlue® Cell Viability Assay. *P ≤ 0.05 vs. control 
group. The values presented are the means ± SD of four independent experiments, n = 4.
TaBlE 1 | The effect of DNICs on cell viability over time (15 min, 60 min, and 10 h).
Name of 
experiment
Fibroblasts Fibroblasts with doxorubicin Cardiomyocytes
Time 15 min 60 min 10 h 15 min 60 min 10 h 15 min 60 min 10 h
Cell (Control) 5,639 5,355 9,869 8,592 7,642 7,311 7,979 7,035 5,527
DNIC#3 13,135 16,622 84,602 7,004 8,122 23,033 9,837 11,290 12,90
DNIC#4 15,498 19,497 44,838 9,927 11,795 21,148 11,053 11,043 11,361
DNIC#6 13,290 18,401 45,315 8,357 10,187 11,982 9,290 9,930 11,618
Negative control 1, 209 1,213 1,230 1,215 1,250 1,244 1,210 1,225 1,216
Data are presented as mean ± SD of three independent experiments.
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Effects of DNICs on Doxorubicin-Induced 
Toxicity in Fibroblasts
Studies demonstrated that doxorubicin plays an important role 
in the cancer therapy-induced cardiomyopathy (Adão et  al., 
2013; Truong et al., 2014). To study the protective effects of 
DNICs on doxorubicin-induced toxicity, a doxorubicin-induced 
toxic model on fibroblasts was used. Cells were pretreated with 
DNICs and then supplemented them with doxorubicin, a well-
known cytostatic anti-cancer agent, which is used to treat breast 
cancer (Agudelo et al., 2016). The results showed that short-term 
treatment of cells with doxorubicin caused a decrease in cell 
viability (Figure 4A). At the same time, incubation of cells with 
DNICs + doxorubicin showed an increase in cell viability over 
time (Figure 4A; 15, 60 min).This indicated that DNICs reduced 
the toxic effect of doxorubicin on cells, and this protective effect 
developed over time. It should be noted that the maximum toxic 
effect of doxorubicin was observed only after 10 h (P  <  0.05, 
Figure 4B). Long-term treatment of cells with DNICs + 
doxorubicin increased cell viability and protected cells from the 
toxic effects of doxorubicin (P < 0.05, Figure 4B). The maximum 
effect of DNICs was also observed after 10 h. After 10 h, the cell 
viability was slowly reduced, however, even after 35 h the cells 
treated with DNICs had a higher viability compared to control 
cells (not treated with DNICs). All DNICs showed a protective 
effect however, DNICs #3 and #4 had the most pronounced 
protective effect. The exact values  of the fluorescence intensity 
after treatment of DNICs+doxorubicin are presented in Table 1.
Thus, the results showed that doxorubicin caused a decrease 
in cell viability, whereas cells treated with DNICs maintained 
a higher viability, in particular, their survival was 2–3 times 
higher than that of untreated cells. These data indicate that with 
DNICs have cytoprotective properties. These results also showed 
that DNICs # 3, # 4 are the most effective protectors against 
doxorubicin-induced cytotoxicity in fibroblasts.
Therefore these data indicate that DNICs are effective long-
acting cytoprotectors that protect cells from the toxic effects of 
doxorubicin.
Effects of DNICs on the Mitochondrial 
Membrane Potential of Fibroblasts and 
Rat Cardiomyocytes
Mitochondrial dysfunction is reported to have occurred with 
ischemia (Galluzzi et al., 2009; Yang J-L et al., 2018; Liu et al., 
2019). Reports show that some chemical compounds that 
can selectively accumulate in mitochondria, reducing their 
membrane potential, have protective properties and can be used 
to prevent severe disorders after ischemia and a stroke (Wang 
et al., 2009; Hou et al., 2019; Hu et al., 2019; Liu et al., 2019).
To identify the effect of DNICs on mitochondrial function, 
we examined the effect of DNICs on mitochondrial membrane 
potential fibroblasts and rat cardiomyocytes. The results indicated 
that DNICs (#3, #4, and #6) decreased the ΔΨm in 2–3 times in 
fibroblasts (Figure 5А). Indeed, the results showed that DNICs 
(#3, #4 and #6) also reduced the level of ΔΨm by 2–3 times in 
rat cardiomyocytes (Figure 5B). Above all, these results showed 
that DNICs affected on the mitochondrial function of cells. We 
suppose that DNICs are organizing an excess charge leakage 
through the mitochondrial membrane.
Effect DNICs at Cell Cycle of Fibroblasts
In order to further study the mechanism of action of DNICs, 
we investigated the effect of these compounds on the cell cycle 
of fibroblasts by flow cytometry. Cells were seeded in culture 
flasks, and before sowing, living and dead cells were counted by 
trypan blue staining (Ruano et al., 2003). The results showed that 
before DNICs treatment 93.75% of the cells were alive and only 
6, 25% were dead (Table 2). Then DNICs #3, #4 were added to 
the experimental flasks, and growth medium was added to the 
control flasks. After incubation for 24 h, the cells were analyzed by 
flow cytometry. In parallel aliquots of cell suspension were taken 
before cell fixation and the number of living and dead cells was 
counted again using trypan blue staining. The results showed that 
the number of dead cells after treatment with DNIC#3 was 7.8%, 
and after processing with DNIC#4 was 9.7% (Table 2). These 
FIgURE 4 | Effects of DNICs on cell viability of fibroblasts, treated with doxorubicin for 60 min (a) and 35 h (B). DNICs (2 × 10-4 M) were added to HLEF-104 
cells, then doxorubicin (1.4 × 10-4 M, 20 min after DNICs treatment) was added, cell viability was tested in fibroblasts by AlamarBlue® Cell Viability Assay after 
doxorubicin-induced toxicity. *P ≤ 0.05 vs. control group. The values presented are the means ± SD of four independent experiments, n = 4.
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data indicate that DNICs are not cytotoxic compounds. Then, 
the effect of these compounds on the fibroblast’s cell cycle was 
studied by flow cytometry. Using the histogram of fluorescence 
intensity, we isolated cells in the SubG1, G1, S, and G2/M phases 
of the cell cycle. As can be seen from Figure 6, the G1 and S 
phases were practically the same for the control and experimental 
samples (after incubating the cells with DNIC#3 and #4). Phase 
S, at which DNA replication of the cell nucleus occurs was 
18.17% for the control sample, 14.35% for DNIC#3 and 11.95% 
for DNIC#4. However, these differences were not statistically 
significant (Figure 6). In addition, the phase of cell division 
(G2/M) for control cells was 21.21%, and for experimental cells 
after incubation with DNIC#4, this phase was 21.67%, and for 
DNIC#3 it decreased slightly to 16. 50% (Figure 6). However, no 
significant difference in the cell division (G2/M) was observed 
between control and experimental samples (P > 0.05).
Thus, these data indicated that DNIC#3 and #4 were not affected 
the proliferation of fibroblasts and not stimulate their growth.
Effect of DNICs on the level of glutathione 
in Fibroblasts and Rat Cardiomyocytes
Studies show that some cardiovascular drugs may also have 
antioxidant properties, as has been shown for some calcium 
channel blockers and β-adrenoceptor antagonists (Taddei 
et  al., 2001). Several synthetic compounds, including free 
radical scavengers and free radical degrading agents, are 
currently under investigation in different clinical settings, 
including diabetes mellitus and acute ischemic stroke, in 
which neuroprotective effects have demonstrated (Margaill 
et al., 2005). To investigate whether DNICs have antioxidant 
properties, we assessed the effect of DNICs on the level of 
the reduced glutathione in fibroblasts and cardiomyocytes. 
The results showed that DNIC #3, #4, and #6 did not affect 
the level of the reduced glutathione either in fibroblasts or in 
cardiomyocytes (Figures 7A, B, respectively). Thus, DNICs 
maintained the intracellular GSH level.
Effect of DNICs on the level of Reactive 
Oxygen species
Cellular redox homeostasis is maintained by the balance between 
ROS generation and successful elimination of ROS by cellular 
antioxidant capacity (Xiao et al., 2018). It is reported that nitric 
oxide, generated by high concentrations of DNICs, interacts 
in mitochondria with superoxide and forms peroxynitrite 
(ONOO-), which is a powerful oxidizing agent (Galijašević, 2013; 
Scicinski et al., 2015; Ferrer-Sueta et al., 2018). To investigate the 
involvement of DNICs in oxidative stress, we studied the effect 
of DNICs on the level of ROS in fibroblasts (Figure 8). The 
results showed that, during the incubation of cells with DNICs, 
compounds #3 and #4 were not significantly increased the level 
of ROS, whereas compound #6 had no effect on the level of ROS 
in fibroblasts. Thus, no significant difference in the level of ROS 
was observed between control (no DNICs) and low dose of 
DNICs (2 × 10-4 M) samples (P > 0.05).
FIgURE 5 | Effects of DNICs on the mitochondrial membrane potential of fibroblasts (cell line HLEF-104) (a) and rat cardiomyocytes (cell line H9c2) (B). Cells were 
treated with DNICs (2 × 10-4 M) or without (control) for 15 min, then JC-1 was added. The ratio of red fluorescence (mitochondrial JC-1) to green fluorescence 
(cytoplasmic JC-1) was used to calculate the mitochondrial potential. *P ≤ 0.05 vs. control group. The values presented are the means ± SD of four independent 
experiments, n = 4.
TaBlE 2 | Determination of cytotoxicity of DNIC on fibroblasts.
Name of experiment Total number of cells Number of living cells Number of dead cells/ml Cytotoxicity index, %
Before the addition of DNIC#3 to cells 25,600 24,000 1,600 6.25
After the addition of DNIC#3 to cells 25,600 23,600 2,000 7.8
Before addition of DNIC#4 to cells 25,600 24,100 1,500 5.8
After addition of DNIC#4 to cells 25,600 23,100 2,500 9.7
Data are presented as mean ± SD of three independent experiments.
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FIgURE 7 | Effect of DNICS on the level of glutathione in fibroblasts (a), in rat cardiomyocytes (B). HLEF-104 or H9c2 cells were either kept untreated or treated 
with DNICs (2 × 10-4 M) for 15 min and intra cellular GSH was measured as described under Materials and Methods section. Results are presented as mean ± SD 
of three independent experiments. Differences between untreated control and DNICs treated cells are significant at *p ≤ 0.05 with ANOVAs followed by Tukey’s 
post hoc test.
FIgURE 6 | Flow cytometric analysis of effect of DNICs on cell-cycle of HLEF-104 cells. The cells were treated with DNICs (2 × 10-4 M) and untreated (control) for 
24 h, samples were analyzed using FACS (Calibur Flow Cytometer, Becton Dickinson, USA). The cell cycle phase profile of HLEF-104: (a) Control, (B) DNIC#3, 
(C) DNIC#4. (D) Graphical presentation of distribution (%) of cells in different phases of cell cycle. The values in the bars indicates the percent population of cells in 
respective cell cycle phases. Results are presented as mean ± SD of three independent experiments.
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Therefore, the above results indicate that DNICs don’t affect at 
the level of ROS at this dose administration.
Effect of DNICs on aTPase activity in 
Fibroblasts Cell lysates
Data on the effect of NO on ATPase activity are inconsistent. 
It was previously shown that NO donors inhibit the activity of 
brain and pig kidney Na+/K+–ATPase (de Lourdes Barriviera, 
2005). At the same time, it was demonstrated that NO regulates 
cardiac intracellular Na+ and Ca²+ by increasing the activity 
of Na+/K+–ATPase (Bogdanova et al., 2016). In particular, 
NO (spermine-NONO-ate) stimulated Na+/K+–ATPase via 
phospholemman phosphorylation and thereby limits Na+ 
and Ca2+ were overloaded and arrhythmias (Pavlovic et al., 
2013; Lu et al., 2015). To further study the role of DNICs, we 
assessed the effects of DNICs on the level of ATPase activity 
in fibroblasts. The results revealed that the DNIC#3 slightly 
increased the level of ATPase activity, and the DNIC#4 and #6 
slightly lower the level of activity of this enzyme (Figure  9). 
However, these differences were not statistically significant. 
Above all, these results showed that DNICs have not affected 
the level of ATPase in the fibroblasts it remained constant 
during the processing of DNICs.
Effect of DNICs on Total aTP in Fibroblasts 
Cell lysates
Studies show that nitric oxide reduced ATP level by about 
50% in nerve axons and 2016DNICs on the level of total ATP 
in fibroblasts. The results showed that DNIC#4 and #6 slightly 
increased the level of ATP in the cell (Figure 10). In general, 
we have established that DNICs does not affect the level of 
ATP. Taken together, the above results indicated that DNICs 
maintained the ATP equilibrium in cell.
DIsCUssION
Donors of NO are widely used drugs for the treatment of 
cardiovascular diseases (Katsumi et al., 2007; Ahmad et al., 
2018). It is known that NO ensures the normal functioning of 
FIgURE 8 | Effect of DNICs on the level of ROS in human lung embryonic 
fibroblasts.HLEF-104 cells were either kept untreated or treated with DNICs 
(2 × 10-4 M) and intra cellular ROS generation was measured [in terms of 
peroxide using dichlorofluorescein diacetate (DCF-DA)] as described under 
Materials and Methods section. Data are presented as mean ± SD of three 
independent experiments. Differences between control and DNICs treated cells 
are significant at *p ≤ 0.05 with ANOVAs followed by Tukey’s post hoc test.
FIgURE 9 | Effect of DNICs at specific ATPase activity in lysates, prepared 
from fibroblasts. Lysates (1.5 mg/ml) were preincubated 15 min at 4 °C 
with no additions (1) or in the presence of DNIC#3, DNIC#4 or DNIC#6. 
Then the ATPase activity was measured as described under Materials and 
Methods section. Data are presented as mean ± SD of three independent 
experiments. Differences between control and DNICs treated cells are 
significant at *p ≤ 0.05 with ANOVAs followed by Tukey’s post hoc test.
FIgURE 10 | Effect of DNICs on total ATP in fibroblasts cell lysates. 
HLEF-104 cells treated with DNICs (2 × 10-4 M) or untreated (control) and 
incubated for 15 min at 37 °C, 5% CO2. Then prepared cell lysates according 
to protocol and total ATP was measured as described under Materials and 
Methods section. Data are presented as mean ± SD of three independent 
experiments. Differences between control and DNICs treated cells are 
significant at *p ≤ 0.05 with ANOVAs followed by Tukey’s post hoc test.
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the cardiovascular system in physiological conditions and its 
adaptation in conditions of pathology (Bian et al., 2008; Divakaran 
and Loscalzo, 2017). Development of NO delivery systems, i.e., 
the synthesis of new representatives of low molecular weight NO 
donors (nitrates, nitrites, nitramines, 1,2-diazeta-1,2-dioxides, 
guanidines, furoxanes, oximes, sydnonimines, diazeniumdiolates 
(NONOates), S-nitrosothiols, nitrosyl metal complexes) and 
the development of macromolecular NO-releasing molecules 
(dendrimers, polymers/films, particle-type and coating 
platforms for NO delivery) is becoming increasingly important 
in biomedical applications of NO (Granik and Grigor’ev, 2002; 
Carpenter and Schoenfisch, 2012; Kim et al., 2014; Sanina et al., 
2015). Most of the available low molecular NO donors have 
essential drawbacks: organic and inorganic nitrates induce nitrate 
tolerance; sydnonimines yield superoxide anions together with 
NO release, thus forming carcinogenic peroxynitrite (ONOO-) 
and giving rise to pathogenic conditions in vivo; wide application 
of NONO-ates, effective class of organic NO donors, is limited by 
their high cost; S-nitrosothiols are unstable upon storing and are 
cytotoxic because in the presence of redox agents they form thiol 
radicals recombining quickly to form disulfides and nitrosonium 
ions, which hydrolyze to yield nitrite anions. Thus, with the 
exception of cyanonitrosyl metalates [M(CN)xNOy]n, which 
might accumulate cyanides upon decomposition, most of the 
available compounds and pharmaceutical substances are able to 
control the NO amount in vivo are synthetic organic compounds 
(McCleverty 1979; Darius et al., 1984; Torfgard and Ahlner, 1994; 
Keefer et al., 1996; Rosenkranz et al., 1996; Anthony and Rhodes, 
1997; Blackburn et al., 1998; Oszajca et al.,1998; Gaston 1999; 
Fitzhugh and Keefer, 2000; Lee et al., 2001; Wöhrle et al., 2003; 
Morphy et al., 2004; Sanina et al., 2015). However, the discovery 
of the role of intracellular nitrosyl non-heme proteins in the 
biochemistry of NO has led to the rapid development of a new 
line of research based on the use of synthetic analogues of these 
highly reactive nitrosyl cell intermediates as prodrugs that release 
NO (Constanzo et al., 2001; Butler and Megson, 2002; Yang et al., 
2002; Turella et al., 2003; Tsai et al., 2004; Lancaster 2010; Islam 
2015; Sanina et al., 2015). These complexes are models of the 
active sites of nitrosyl non-heme [Fe-S] proteins existing in all 
living organisms, from bacteria to mammals (Butler and Megson, 
2002; Lewandowska et al., 2011; Sanina et al., 2015). These 
mono- and binuclear nitrosyl iron complexes with functional 
sulfur-containing ligands have some advantages over other low-
molecular NO-donating agents: these compounds release NO at 
physiological pH values without any activation (photo, thermal 
or redox), they can be isolated in the crystalline state, and no toxic 
products form upon their decomposition, this being favorable 
for biological and medical investigations and applications 
(Sanina et al., 2015). Recently it was obtained and characterized 
a new family of cationic water soluble dinytrosyl iron complexes 
(DNICs) with S-donor ligands, such as thiocarbamide and its 
derivatives (Sanina et al., 2014a; Sanina et al., 2015; Sanina et al., 
2016; Shmatko et al., 2017a). These compounds have several 
advantages over previously synthesized NO donors. Firstly, 
they are water-soluble compounds. Secondly, it was shown that 
these DNICs are more effective NO donors compared to the 
commercial NO donor diethylenetriamine and have more than 
twice the ability to generate NO (Sanina et al., 2014b; Sanina 
et al., 2015). Their structure and properties has been studied 
previously by X-ray diffraction analysis, IR-, Mössbauer- and 
EPR spectroscopy (Figure 1, Supplement Material) (Shmatko 
et al., 2017a). DNICs serve as carriers of the “ready-to-use”, iron-
stabilized form of NO (Kapelko et al., 2017; Schiewer et al., 2019). 
It was shown that the mechanism of NO release from iron–sulfur 
complexes in aqueous solution is similar to the generation of NO 
in the solutions of monocation iron complex with thiocarbamide 
[Fe(SC(NH2)2)2(NO)2]ClH2O (Sanina et al., 2014a; Sanina et al., 
2015). This mechanism involves the dissociation of the Fe–NO 
bond and the replacement of NO by the aqua ligand by adding 
water to the free coordination center of iron (Sanina et al., 2015). 
Apparently, stable nitrosyl intermediates formed during the 
decomposition of DNICs are present in solutions, which provide 
long-term NO-donor properties of the complexes (Sanina et al., 
2015). The effect of various DNICs depends on their chemical 
and electronic structure, the reactivity of nitrosyl groups, amount 
of NO generated and the duration of its release.
Depending on this, some DNICs exhibit cytotoxic properties 
and are potential antitumor drugs but other DNICs exhibit 
cytotropic, cytoprotective and vasodilation properties and 
therefore are potential drugs for the treatment of cardiac diseases 
and cardiac complications after chemotherapy.
As follows from a comparative analysis of the molecular and 
crystalline structure of DNICs compounds, the conformation 
of the [Fe (SR)2 (NO)2]2+ cation changes depending on the 
nature of the counter ions in the structure, which is due to the 
rotation of thiocarbamide ligands around Fe–S and S–C bonds 
In addition, the type of intermolecular interaction in salts of [Fe 
(SR)2 (NO)2]2+ with various counter ions affects the structure of 
thiocarbamide ligands as well as the structure and reactivity of 
nitrosyl groups (Sanina et al., 2015). General formula of cationic 
mononuclear DNICs is [Fe (SR)2 (NO)2] n + X-, where n = 1-4, 
X = acid residue, R represents thiourea, as well as its derivatives 
by the reaction of aqueous solutions of iron salts (Aldoshin et al., 
2016). However, the molecular mechanism of DNICs action and 
their metabolic effects in cells has not been sufficiently studied. 
In this paper we first studied the metabolic effects of DNICs at 
human fibroblasts and rat cardiomyocytes. We proceeded from 
the fact that earlier, for other NO donors, cytoprotective and 
cardioprotective effects were shown at their low concentrations 
(<1 µmol) (Davis, et  al., 2001; Naseem, 2005; Lewandowska 
et al., 2011; Xia and Vanhoutte, 2011; Omar et al., 2016; Komatsu 
et al., 2018; Hou et  al., 2019; Raffetto et al., 2019; Taysi et al., 
2019; Tegeder, 2019). It was previously established that DNICs 
(0.4 × 10-5 M) decompose to form NO in the first second after 
dissolution in an anaerobic aqueous solution (Figures 2–4, 
Supplement Material) (Sanina et al., 2013; Sanina et al., 2014a). 
In particular, the maximum amount of NO generated by DNIC 
# 3 at pH 7 was ~ 16 nM, complex 4 was 8 nM, complex # 6 was 
2.5 nM after 50 s (Figures 2–4, Supplement Material) (Sanina 
et al., 2014). Based on this we weighed (2 × 10-4 М) of DNICs and 
then checked the generation of NO using the electrochemical 
method (Figure 1). According to these data, DNICs were 
generated from 8 to 16 nmol of NO. In particular, DNIC#3 at 
pH 7 generated~ 16 nM of NO, and DNIC#4 released 8 nM of 
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NO after 50 s. Thus, these values are consistent with previously 
published data on the release of NO (Sanina et al., 2014a). Some 
threshold concentration of the cytotoxicity effect of NO has been 
demonstrated previously (Liu et al., 2019). The threshold doses 
for NO• induced cytotoxicity were shown to be 150 µM min in 
TK6 cells and 300 µM min in NH32 cells, respectively. However, 
in our work, DNICs were generated from 8 to 16 nmol of nitric 
oxide (this amount NO is lower in 20,000 times compare with 
amount of NO, used by Li et al.: 150 and 300 μM). As mentioned 
above NO donors demonstrated cytotropic and cardioprotective 
effects at low concentrations (<1 µmol).Therefore, we chose the 
initial concentration DNICs (2 × 10-4 М), which, when dissolved, 
released 8 to 16 nmol of NO.
Furthermore in this study, our findings suggested that 
DNICs were not only non-toxic, but even exhibited cytotropic 
properties in fibroblasts and rat cardiomyocytes. We studied 
the effect of DNICs on cell viability for a short and long time. 
It was found that the effect of DNICs on cell viability manifests 
itself after 15 min, since an increase in fluorescence intensity 
is observed. However, the maximum effect was observed after 
10 h. Then, the cell viability decreased, however, even 30 h later 
it remained 3–5 times higher than in the control cells, which 
were not treated with DNICs. We believe that DNICs increased 
the activity of mitochondrial NADH dehydrogenase, metabolic 
processes occur more intensively under the influence of DNICs 
and thereby increase the cell viability. These results indicate 
that DNICs are cytotropic agents. It was previously shown that 
NO able to trigger mitochondrial biogenesis in cells as diverse 
as brown adipocytes and 3T3-L1, U937, and HeLa cells (Nisoli 
et al., 2003; Lascaratos et al., 2012). However, the authors 
indicated that this effect of NO was dependent on guanosine 3′, 
5′-monophosphate (cGMP) and was mediated by the induction 
of peroxisome proliferator-activated receptor γ coactivator 1α, a 
master regulator of mitochondrial biogenesis. It is possible that 
in our case, DNICs also affect the mitochondrial biogenesis, 
however, their mechanism of action is different. Nisoli et al. 
showed that the NO–cGMP-dependent pathway controls 
mitochondrial biogenesis and body energy balance. In our work, 
we showed that DNICs increased the activity of mitochondrial 
dehydogenases, however, did not affect the level of ATP. We 
suppose, that treatment with DNICs led to enhancement of the 
activity of mitochondrial dehydrogenases, and by this prevent 
cells from induction of apoptosis. We observed the cells under 
a microscope before measuring viability; cells looked attached 
to the surface and spread out. These cells are adhesive, and if 
apoptosis occurred, they would round off, detach from the 
surface and begin to swim in a growth medium. The number of 
cells did not change under the influence of DNICs and we did 
not observe an increase in the number of apoptotic cells either.
We also studied the cytoprotective effect of DNICs against 
toxicity induced by doxorubicin, anti-tumor drug. It is well-
known that doxorubicin is highly toxic and causes many 
complications in the cardiovascular system after chemotherapy 
treatment. It had been reported, that doxorubicin is antibiotic of 
the anthracycline series and has antimitotic and anti-proliferative 
effects on cells (Rivankar, 2014; Dubbelboer et al., 2017). It is 
known in the literature that doxorubicin induces oxidative stress 
by ROS overproduction and accordingly reduces the level of 
glutathione in the cell, diminishes ROS-scavenging activities 
(e.g. catalase and glutathione peroxidase), significantly decrease 
the inner mitochondrial membrane potential and ATP level 
(Seraﬁno et al., 2000; Childs et al., 2002; Mukhopadhyay et al., 
2009; Kuznetsov et al., 2011; Sifaoui et al., 2014). This manifests 
the cytotoxic effect of doxorubicin. Doxorubicin binds to DNA 
in mitochondria, destroys it, decrease the membrane potential, 
which leads to an increase in ROS and induction of apoptosis, 
followed by cell death. The principle of using doxorubicin in 
oncology is based on this. We included doxorubicin as a control 
to compare its toxic effect on cell viability with the protective 
effect of DNICs and to demonstrate a decrease in its toxicity due 
to preliminary incubation of cells with DNICs. Results showed 
that doxorubicin caused a decrease in the cell viability, whereas 
the cells that were treated with compounds #3, 4, and 6 retained 
a higher viability: their survival was two- to three times higher 
than that of the untreated cells. DNICs#3 and #4 have been 
shown to be the most effective cytoprotectors. Therefore, our 
findings demonstrate that DNICs are effective cytoprotectors 
with a long-term effect, which protect cells from the toxic 
action of doxorubicin.We also studied the effect of DNICs at the 
mitochondrial membrane potential on cells. Our data shown 
that incubation cells with DNICs decreased mitochondrial 
transmembrane potential (ΔΨm) not significantly, just in 2–3 
times. Results demonstrated that effect of DNICs on membrane 
potential was soft, moderate and, probably, short-term and 
reverse. It was previously shown that long-term treatment 
with doxorubicin also resulted in a quick drop in membrane 
potential (in 5 times), followed by detachment up to 90% cells 
and cell death (Kuznetsov et al., 2011). In our case, we believe 
that this short-term drop in the membrane potential is useful for 
the cell, as it allows cells to get rid of excess charge and thereby 
reduce the formation of ROS, prevent apoptosis and protect cells 
from death. In addition, we suppose that slight depolarization 
of the mitochondrial membrane is short-term and reversible, 
and after a while the normal ΔΨm is restored. When setting up 
the experiments, we also observed the state of the cells under 
a microscope. These cells are adhesive, in a normal state they 
are spread over the surface. Microscopic analysis of the cells 
showed that after preliminary treatment of the cells with DNIC 
and subsequent treatment with doxorubicin, the cells did not 
round up, they remained attached to the surface, indicating their 
normal viability.
It’s obvious that the mechanism of DNICs action on the 
membrane potential is different from the mechanism of action 
of doxorubicin. It has previously been reported that mechanism 
of action of doxorubicin includes the cooperation with DNA, 
generation of free radicals, and direct effect on cell membranes 
with the suppression of the synthesis of nucleic acids (Dubbelboer 
et al., 2017). Therefore, the treatment of cancer with doxorubicin 
is accompanied by an increase in the production of free radicals 
in the mitochondria, which have a deleterious effect on the 
structure of both tumor and normal cells as a result of oxidative 
stress (Cooley, 2007). This is accompanied by numerous side 
effects of doxorubicin, which are toxic to the whole body during 
the chemotherapy. For example, the cardiovascular system 
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disorders include cardiomyopathy, heart failure, and arrhythmia 
(Koleini and Kardami, 2017). This process directly depends 
on the mitochondrial membrane potential: the higher the 
latter, the greater amounts of free radicals are produced by the 
mitochondria. Thus, most adverse effects of doxorubicin on the 
normal cells are associated with the oxidative stress. However, 
this oxidative stress can be reduced by providing the leakage 
of excess charge through the mitochondrial membrane (Wang 
et al., 2009, Montaigne et al., 2012; Islam, 2017). This protective 
mechanism is called the uncoupling of oxidative phosphorylation. 
It is used by cells in vivo but can also be induced by synthetic 
compounds. Natural mechanisms of uncoupling do not always 
cope with their functions. It has been shown that reduction in 
mitochondria membrane potential is often seen in pathological 
conditions. Many pathological conditions have been described 
in which mitochondrial hyperpolarization occurs, accompanied 
by an increased level of ROS in the mitochondria, which leads 
to a deterioration in the functioning of the cell as a whole. This 
situation occurs in obesity, impaired carbohydrate metabolism, 
as well as in pathologies associated with the development 
of oxidative stress: ischemic tissue damage, Parkinson’s and 
Alzheimer’s disease, autoimmune diseases (Skulachev, 1996; 
Silachev et al., 2018). The use of uncouplers capable of regulating 
by increasing the proton conductivity of mitochondria is capable 
of eliminating the negative effects caused by these pathological 
conditions, in particular, by controlling the level of ROS 
generation by mitochondria (Korshunov et al., 1997; Rolo and 
Palmeira, 2006). The vast majority of uncouplers are negatively 
charged molecules, anions, the uncoupling mechanism of which 
is similar to fatty acid anions (RCOO-). It was found that certain 
chemical agents selectively accumulate in mitochondria and 
reduce their membrane potential and, thus, exhibit cytoprotective 
properties (Normoyle et al., 2015; Kanemoto et al., 2019; 
Khailova et al., 2019). These compounds can be used to prevent 
severe neurological disorders after ischemic stroke (Kwok et al., 
2010; Perez-Pinzon et al., 2012; Normoyle et al., 2015). However, 
the possibility of medical use of such molecules is limited to an 
extremely small therapeutic window—the difference between 
therapeutic and toxic doses of the drug. The fact is that a sharp 
decrease in the membrane potential leads to a disruption in the 
main function of the mitochondria–ATP synthesis, the universal 
“fuel” necessary to maintain the vital activity of the cell and the 
organism as a whole (Nabben et al., 2011).
Currently, a group of academician Skulachev has created a 
number of substances—cationic uncouplers, whose chemical 
structure allows them to selectively accumulate in mitochondria 
and reduce excess mitochondrial potential (Lyamzaev et al., 2018; 
Silachev et al., 2018; Genrikhs et al., 2019). At the same time, the 
effect of cationic uncouplers is self-regulating—since these are 
negatively charged molecules, the rate of their penetration into 
the mitochondria is directly proportional to the mitochondrial 
potential. However, the mitochondrial potential decreases with 
increasing concentration of the cationic uncoupler inside the 
mitochondria. It was shown that the new cationic uncoupler—
rhodamine-19 butyl ether (C4R1) effectively accumulates in 
mitochondria to a certain concentration, without disturbing 
their vital functions. In experiments on rats—models of ischemic 
stroke, it was shown that the introduction of C4R1 after a 
reversible violation of cerebral circulation significantly reduced 
the scale of brain damage to animals and related neurological 
disorders (Korshunova et al., 2017; Lyamzaev et al., 2018; 
Silachev et al., 2018; Genrikhs et al., 2019). It should be noted that 
preventing the production of oxygen radicals in mitochondria 
is a fundamental principle in the fight against many diseases. 
Such compounds will have the properties of an uncoupler that 
normalizes mitochondrial potential. Clinical studies on the use 
of such molecules in the treatment of a number of diseases are 
being actively conducted. Finally, nitroglycerin has been shown to 
induce a protective phenotype that limits damage after ischemia 
and reperfusion. Nitroglycerin protects against post-ischemic 
endothelial dysfunction in particular, in part, by impairing the 
opening of the mitochondrial permeability transition pore (Gori 
et al., 2008; Divakaran and Loscalzo, 2017).
We assume that DNICs may uncouple of oxidative 
phosphorylation in the cell and thereby lower the mitochondrial 
membrane potential (Aly and Domenech, 2009). This 
assumption is based on the structure of DNICs. The total 
DNICs formula ([Fe (SR)2 (NO)2] n + X-) corresponds to the 
general formula of cationic uncouplers: (X–Z)n+An-, where “X” 
is a group containing heteroatoms such as –S-, –N-, –O-; “Z” is a 
group that can protonate at physiological pH values  and provide 
targeted delivery of the entire compound to mitochondria; “A” 
is the counterion; “N” is an integer from 1 to 3, as well as its 
tautomeric forms, solvates, salts, isomers or prodrugs, and a 
pharmacologically acceptable carrier. In addition, DNICs have 
negative charge and they can penetrate through membranes. 
We suppose, that tested DNICs have a double mechanism of 
action, in particular, they exhibit both the ROS-scavenging 
effect and mitochondrial effect. DNICs include two parts: NO 
donor and [Fe–S] cluster (mitochondrial targeting). NO is high 
reactivity because of its electronic conﬁguration, i.e., existence 
of an unpaired electron on the π-molecular orbital (Wong 
et al., 1989). According to this released NO can interact with 
radicals (O2-, H+) and prevent the oxidative stress, working as 
antioxidant. The iron in the [Fe–S] cluster is monovalent and 
therefore it can interact with protons and pass into the divalent 
or trivalent state. Therefore, the [Fe–S] cluster can work as soft 
uncoupler and cause a drop in the mitochondrial potential. In 
addition, high afﬁnity of NO for Fe2+ results in the interaction 
of nitric oxide with a variety of iron-containing proteins, for 
example, ribonucleotide reductase, ferritin, [Fe–S]clusters 
of NADH-reductase, NADH dehydrogenase (Rahmanto et 
al., 2012; Shmatko et al., 2017b). It is known that NADH-
dehydrogenase complex, also called complex I is the first multi-
protein complex of the electron transport respiratory chain. In 
relation to human proteins, complex I is often called NADH-
dehydrogenase (Birrell et al., 2009). Many copies of the complex 
are located in the inner mitochondrial membranes of eukaryotic 
cells. NADH-dehydrogenase complex consist from one flavin 
mononucleotide and from 8 to 9 iron-sulfur clusters (prosthetic 
groups) (Voet and Voet, 2004). This complex plays a central role 
in cellular respiration and oxidative phosphorylation: almost 
40% of the proton gradient for the synthesis of ATP is created 
precisely by this complex (Efremov et al., 2010). Moreover, it is 
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own that NO inhibits the mitochondrial respiratory pathways 
(Montaigne et al., 2012). We suppose that DNICs generate 
the NO, which interacts with [Fe–S] clusters of NADH–
dehydrogenenase, change its conformational state and enhances 
the activity of NADH–dehydrogenase. In addition, the ligands, 
remaining after generation of nitric oxide, [Fe–S] clusters can be 
used as prosthetic groups of NADH dehydrogenase and thereby 
increase its activity. NADH–dehydrogenase complex oxidizes 
NADH, which is formed in the matrix during the tricarboxylic 
acid cycle (Berg et al., 2006). Electrons from NADH are used 
to restore the membrane carrier, ubiquinone Q, which transfers 
them to the next complex of the electron transport chain of 
mitochondria, complex III, or the cytochrome bc1 complex 
(Berg et al., 2006). As a result of DNICs effect, NADH-
dehydrogenases break down a larger amount of NADH and a 
large number of protons (electrons) are formed, which is used 
in various metabolic and energy processes in the cell. As a 
result, cell viability increases. However, the increased activity of 
dehydrogenases after a certain time leads to the accumulation 
of excess charge in the mitochondria (Murphy, 2009). Excessive 
number of electrons can lead to an increase in the formation 
of ROS, oxidative stress and, as a result, cell death (Murphy, 
2009). We suggest that DNICs (in particular, NO and Fe–S 
clusters) are also able to attract electrons to themselves, which 
leads to the removal of excess charge through the mitochondrial 
membrane. The consequence of this is the uncoupling of 
oxidative phosphorylation, accompanied by a decrease in 
ROS, a decrease in the mitochondrial membrane potential and 
a suspension of  ATP synthesis (Yang T. et al., 2018). This is a 
protective effect of DNICs. However, it is likely that the decrease 
in membrane potential is insignificant and short-term, since a 
sharp decrease in membrane potential leads to disruption of 
ATP synthesis. After some time, the membrane potential returns 
to its normal state. It is known that the reaction catalyzed by 
complex I is reversible, this process is called aerobic succinate-
induced reduction of NAD + (Grivennikova et al., 2007). Under 
conditions of high potential on the membrane and an excess 
of  reduced ubiquinols, the complex can reduce NAD  + using 
their electrons and pass protons back into the matrix (Kwok 
et al., 2010).
The proposed mechanism of action of DNICs is shown in 
Figure 11. All this together determines their cytotropic and 
cytoprotective properties.
We investigated the effect of DNICs on cell proliferation and, 
in parallel, counted the number of living and dead cells before 
flow cytometry analysis. The results showed that the number 
of dead cells increased slightly after treatment with DNIC by 
only 1–2%. Flow cytometry analysis showed that DNICs did 
not affect cell proliferation. However, we observed an obvious 
increase in the subG1 phase in cells treated with compounds 3 
and 4. We suggest that such a small increase in apoptotic cells 
occurs as a result of mechanical stress, which often occurs in cells 
by excessive pipetting, shaking, or rapid centrifugation >350g 
during cell fixation, resulting in subG1 fragments that occur 
during harvesting and staining.
It has previously been reported that ATPase (Adenosine 
Triphosphatase: EC 3.6.1.3) is an important enzyme for 
maintaining the cell membrane potential, transporting ions and 
regulating cellular volume (Riley and Peters, 1981). We therefore 
tested the effect of DNICs on the ATPase enzyme activity and the 
total amount of ATP in the cells. Our results showed that DNICs 
did not affect the level of ATPase and the total amount of ATP 
in the cell, its level remained constant. Therefore, our findings 
suggested that DNICs are not involved in the signaling pathway 
for the synthesis and breakdown of ATP in the cell.
It was previously found that maintaining the optimal ratio of 
reduced glutathione (GSH) to oxidized (GSSG)—GSH/GSSG 
is an important condition for cell viability (Kim et al., 2010; 
FIgURE 11 | The proposed mechanism of action of DNICs.
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Bachhawat and Yadav, 2018; Parvez et al., 2018). Glutathione 
plays a key role in redox regulation of the main processes of 
cell activity, namely, in regulation of the cell cycle, energy 
production, apoptosis, proliferation, differentiation, protein 
folding, transcription, DNA repair, signaling, and antioxidant 
protection (Traverso et  al., 2013; Lu et al., 2016; Robaczewska 
et al., 2016; Zhang et al., 2018). Glutathione is a low molecular 
weight antioxidant and can participate in non-enzymatic 
antioxidant protection, acting as an effective scavenger (trap) of 
free radicals (Forman, 2016). A decrease in the GSH level below 
normal values serves as an indicator of a violation of the cellular 
redox status and changes in the redox-dependent regulation of 
genes (Rushworth and Megson, 2014; Forman, 2016). Thus, we 
investigated that role of DNICs on the level of glutathione in 
cells. The finding of the study showed that the tested DNICs did 
not affect the level of reduced glutathione in the cells. Moreover, 
this indicates that DNICs does not cause oxidative stress in cells 
and the redox balance is not disturbed. Recent studies have 
shown that GSH accumulates in the nucleus at the beginning of 
the G1 phase, so it can play an important role in maintaining 
the redox status of the nucleus during the cell cycle (Garcia-
Gimenez et al., 2013). In addition, studies have shown that 
cancer cells have an elevated level of glutathione, which allows 
them to quickly divide and be resistant to oxidative stress (Estrela 
et al., 2016). Since the level of glutathione can influence cell 
proliferation, we investigated the effect of DNICs on cell division 
using flow cytometry. We found that DNICs were not affected 
cell proliferation. Taken together the results suggested that since 
DNICs were not affected on the level of glutathione, it retains the 
redox status of the nucleus during the cell cycle and the level of 
cell proliferation was not changed.
Reports show that under normal conditions, the GSH/GSSG 
ratio is 100:1. Maintaining an optimal GSH/GSSG ratio in the cell 
is essential for its normal functioning and survival (Tchouagué 
et al., 2019). Violation of this ratio has a significant impact on 
the processes of signal transduction, control of gene expression, 
cell proliferation, differentiation, the state of cellular metabolism, 
and cell activity in general (Nagapan et al., 2019). The lack of 
GSH exposes the cell to the risk of oxidative damage and leads 
to the accumulation of ROS in the cell. ROS play an important 
role of signaling molecules; however, their accumulation in 
pathological states leads to oxidative stress (Sarniak et al., 2016; 
Ravera et al., 2015). The main source of ROS in cells is oxidative 
phosphorylation. Mitochondrial dysfunction and oxidative stress 
are involved in the pathogenesis of many diseases (Grancara et al., 
2015; Liu et al., 2019). Oxidative stress causes many degenerative 
diseases and cell death. The formation of reactive oxygen species 
with the participation of mitochondria plays an important role 
in the induction of apoptosis in pathophysiological processes in 
neurons, cardiomyocytes, and also in the process of aging (Haller 
et al., 2002; Czarna and Jarmuszkiewicz, 2006; Lin et al., 2012; 
Lin et al., 2012; Kleme et al., 2018; Salimi and Pourahmad, 2018; 
Suski et al., 2018). Therefore, the determination of ROS can 
provide important information about the physiological state of the 
cell and the function of mitochondria (Liu et al., 2019). Based on 
these results, we investigated the role DNICs in formation of ROS. 
As expected, this study showed that showed that DNICs at this 
dose of administration (2.0 × 10-4 M) were not affected the level of 
ROS in the cell, that is, peroxynitrite (ONOO-) was not formed in 
the cell, which has a high oxidative activity. It is possible that the 
DNICs protected cells (fibroblasts and rat cardiomyocytes) from 
ROS by maintaining redox balance. This finding indicated that 
DNICs caused no physiological disorders in fibroblasts and rat 
cardiomyocytes. It is possible that DNICs prevent the production 
of oxygen radicals in the mitochondria, which is a fundamental 
principle in the fight against many diseases.
For the first time we found that DNICs were protective against 
doxorubicin-induced toxicity in fibroblasts. Therefore, our findings 
suggested that DNICs might protect cells in vitro against doxorubicin, 
a known anti-tumor and cardiac toxic anthracycline antibiotic. We 
suggest that DNICs can briefly uncouple the electron transport 
chain and thereby induce the leakage of excess of electrons through 
the membrane and prevent the occurrence of oxidative stress in the 
cell. We have demonstrated here that these DNICs can be used in 
cardio-oncology to maintain or increase the viability of cells of the 
whole body and cardiomyocytes in the treatment of cancer.
CONClUsION
Above all, the study showed that the above mentioned results 
revealed that DNICs have the cytotropic and cytoprotective 
effects on cells.
Moreover, we are first demonstrated that DNICs can 
be regarded as cationic mitochondrial uncouplers. These 
compounds did not disturb the vital metabolic processes in the 
cell, but, on the contrary, demonstrated a protective effect and 
increased the cell viability of fibroblasts and rat cardiomyocytes.
This indicates that DNICs are promising compounds for 
the treatment of cardiovascular diseases (ischemia and stroke) 
and cardiac complications in the treatment of cancer patients. 
Assessing the data obtained from a practical point of view, it can 
be concluded that DNICs are promising candidates for further 
pharmacological studies to develop drugs for the treatment of 
CVD. However, further research is needed on preclinical and 
clinical trials of these compounds.
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